Skip to main content

Table 2 The drug resistant profile of the TBM patients

From: Decreased mortality seen in rifampicin/multidrug-resistant tuberculous meningitis treated with linezolid in Shenzhen, China

D-R type

Total (n = 137)

New cases (n = 119)

Previously treated cases (n = 18)

P value

INH-R

3/90 (3.3%)

2/79 (2.5%)

1/11 (9.1%)

0.330

RIF-R

12/137 (8.8%)

6/119 (5.0%)

6/18 (33.3%)

 < 0.01

MDR

7/137 (5.1%)

3/119 (2.5%)

4/18 (22.2%)

 < 0.01

  1. D-R type, drug resistant type; INH-R, isonaizid resistant; RIF-R, rifampicin resistant; MDR, multidrug resistant; INH resistant plus RIP resistant; New cases, a newly registered episode of TB in a patient who has never been treated for TB or has taken anti-TB medicines for less than 1 month. Previously treated cases: patients who have received 1 month or more of anti-TB medicines in the past
Back to article page

BMC Infectious Diseases

ISSN: 1471-2334

Contact us